From Our Partners
Monday, June 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Aidar Health’s Rapid Patient Triage System Gains Federal Funding From BARDA

by Global Biodefense Staff
September 27, 2021
Aidar Health’s Rapid Patient Triage System Gains Federal Funding From BARDA

Photo via Medical Countermeasures.gov

BARDA is collaborating with Aidar Health, Inc. to develop and validate the company’s Aidar COVID-19 decompensation index (AIDI), a new early warning system that uses MouthLab, a U.S. Food and Drug Administration (FDA)-cleared device, to enable timely intervention in COVID-19 patients at risk for severe illness and rapid deterioration.

Integrated devices and artificial intelligence (AI)-enabled technologies like AIDI have the potential to provide early and actionable health status information to empower individuals and health care providers.

Identifying early signs of COVID-19 disease progression or deterioration (such as difficulty breathing, chest pain, fainting and sudden dizziness or weakness) is crucial to ensuring successful patient outcomes. Delays in accurately detecting these warning signs may worsen prognosis and impact the quality of life of patients. While clinicians can evaluate hospitalized patients more closely, intervening early can be difficult when their patients are being clinically surveilled from home. Robust early warning tools such as MouthLab, when combined with data science, can effectively monitor a large number of individual subjects’ physiological parameters in real-time and detect early signs of deteriorations. This will enable the managing physicians to provide timely intervention and ultimately, help avoid an Emergency Department visit/hospitalization.

AIDI is designed as a multi-sensor-based machine learning technology for real-time automated detection of decompensation. MouthLab and the AIDI are being evaluated for accurate detection of physiological changes early enough to allow timely intervention for COVID-19 patients at risk of deterioration, thereby reducing the likelihood of hospitalization, severe disease, or death. AIDI is based on multiple physiological trends including combination of temperature, blood pressure, electrocardiogram (EKG) data, heart rate, respiration rate, oxygen saturation (SpO2), and other lung functions, which can be useful for the monitoring of not only infections but also cardiovascular diseases.

BARDA is partnering with Aidar to develop and validate the AIDI using Mouthlab (an FDA 510k cleared and CE marked device that measures over 10 vital health parameters) in a cohort of COVID-19 patients, in collaboration with several health systems across the U.S. in a clinical study. By leveraging a demographically diverse user cohort, the study can also increase the understanding of how COVID-19 infections specifically impact different population groups.

MouthLab has the potential to be a commercially available remote monitoring device for daily health assessment. A single breath, in tandem with other sensors, can convey vital health information in real time to individuals and their care providers, enabling enhanced patient care monitoring and management.

From Our Partners
Tags: Artificial IntelligenceASPRAwardsBARDABioinformaticsCOVID-19Editor PickHHSMedicine-HealthPatient Triage

Related Posts

Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Rapid COVID-19 PCR Test Developed at Northwestern Receives FDA Emergency Use Authorization
Biodetection

Rapid COVID-19 PCR Test Developed at Northwestern Receives FDA Emergency Use Authorization

March 19, 2022
There’s No Such Thing as Just-in-Time Healthcare and Public Health Preparedness
Industry News

Appili Awarded $10M in New Biodefense Funding for Tularemia Vaccine Candidate

March 3, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC